On October 22, 2026 Pillar Biosciences, Inc., a leader in oncology-focused next-generation sequencing (NGS) solutions, reported the launch of the MRDTect NPM1 and FLT3 ITD Panel, a research-use-only (RUO), kitted NGS panel for MRD detection in acute myeloid leukemia (AML). As the company’s first MRD product, the panel detects NPM1 exon 12 mutations and FLT3 internal tandem duplications (ITDs) from a single genomic DNA input, down to 0.005% variant allele frequency (VAF). The launch is Pillar’s first step in helping laboratories localize NGS-based MRD testing, bringing ultrasensitive molecular monitoring in-house on their existing NGS infrastructure rather than relying on centralized send-out testing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MRD is a critical prognostic marker in AML, revealing treatment response and relapse risk beyond what morphology can show. The 2025 European LeukemiaNet (ELN) MRD recommendations call for leukemia-specific molecular markers measured at limits of detection of 10⁻⁴ to 10⁻⁵, and introduce ultrahigh-sensitivity NGS for FLT3-ITD-positive AML. Yet laboratories today either send out testing to centralized reference laboratories or test NPM1 and FLT3-ITD separately, using RNA-based qRT-PCR for one and complex hybrid-capture NGS with long-read sequencing for the other. That split adds sample input, cost, hands-on burden, and turnaround time.

"MRD is where precision oncology is heading, and laboratories need tools that make ultrasensitive monitoring practical in-house," said ShiPing Zou, Ph.D., Sr. Director, Product Strategy and Portfolio Management of Pillar Biosciences. " MRDTect NPM1 and FLT3 ITD Panel is our first step in helping laboratories localize NGS-based MRD testing. It brings two of the most informative AML markers into one simple, kitted workflow that runs on the sequencers in their own labs, built on the same SLIMamp chemistry our customers already trust."

Two critical markers, one workflow

The MRDTect NPM1 and FLT3 ITD Panel uses Pillar’s proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology designed with the company’s AI-empowered VersaTile Primer Design tool. Both targets are enriched in a simple, single-tube reaction and sequenced on standard 2 × 150 bp paired-end runs, with no long-read configuration required.

Key specifications and benefits include:

Ultrahigh sensitivity: 100% detection of NPM1 and FLT3-ITD variants at 0.005% VAF (5 × 10⁻⁵) and above, within the ELN-recommended MRD range, with detections observed below that level.
Broad FLT3-ITD coverage: detects ITDs from approximately 3 bp to more than 300 bp, including ultra-long ITDs that challenge existing testing methods.
Simple, rapid workflow: single-tube library prep with about 3.5 hours of hands-on time, under 8.5 hours from DNA to sequencer, flexible stopping points, and sample-to-result in under 48 hours.
DNA-based, low complexity: one genomic DNA input (500–700 ng for a target VAF of 10-4; 700 ng for a target VAF of 10-5) from blood, PBMCs, WBCs, or bone marrow avoids RNA pre-analytical variability and the need to divide specimens across different assays.
Integrated informatics: PiVAT analysis software processes each sample in about 3–10 minutes through a user-friendly interface, with dedicated long-indel and FLT3-ITD calling and built-in QC metrics.
Scalable and economical: low read requirements (≥1.2M paired-end reads for target VAF of 10-4; ≥8.9M paired-end reads for target VAF of 10-5) support cost-efficient, high-throughput, in-house testing.
Together, these capabilities let laboratories run AML MRD testing with Pillar’s kitted reagents and PiVAT software on their existing sequencing instruments, consolidating two tests into one and keeping samples, data, and turnaround time under local control.

Performance demonstrated across internal and partner laboratories

Performance was characterized both internally and at four external partner laboratories, including a large commercial laboratory and an academic cancer center. Across more than 200 libraries from clinical samples and reference materials, the results demonstrate that the workflow can be run independently in a variety of laboratory settings. Median mapping rates exceeded 99% across all specimen classes, with approximately 99.2% of aligned reads on target and balanced NPM1 and FLT3 coverage.

A first step toward localized MRD testing

The MRDTect NPM1 and FLT3 ITD Panel is the initial step in Pillar’s strategy to help more broadly localize NGS-based MRD testing. The company plans to build on the MRDTect platform to bring the same combination of sensitivity, simplicity, and affordability for the analysis of additional hematologic cancers over time.

The MRDTect NPM1 and FLT3 ITD Panel is for research use only. Not for use in diagnostic procedures.

(Press release, Pillar Biosciences, OCT 22, 2026, View Source [SID1234673683])

On October 22, 2026 The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with Georgiamune Inc., a clinical-stage biotechnology company discovering and developing first-in-class therapies that reprogram immune signaling pathways to treat cancer and autoimmune diseases, reported an exclusive worldwide license and collaboration agreement for GIM-621.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. It is one of multiple therapeutic candidates generated from Georgiamune’s research into novel mechanisms governing immune activation, suppression and homeostasis.

Under the terms of the license and collaboration agreement, Stemline receives an exclusive, worldwide license to develop, manufacture and commercialize GIM-621. Georgiamune will receive $45 million in upfront and near-term payments. Georgiamune is also eligible for preclinical, development, regulatory and commercial milestone payments, for a total potential deal value of up to $1.1 billion, plus royalties.

"At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology," said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. "GIM-621 is one of multiple programs to emerge from that work, alongside three programs already in clinical development across autoimmune disease and oncology. This agreement brings Menarini’s global oncology development and commercial capabilities to GIM-621 while allowing Georgiamune to continue advancing a broad pipeline built on distinct immune mechanisms."

"We are delighted to partner with Georgiamune, a company with deep expertise in immuno-oncology which has led to the discovery of GIM-621, a first-in-class oral immunotherapy with promise across multiple solid tumors," said Elcin Barker Ergun, CEO of the Menarini Group. "This program is a strong complement to our solid tumor portfolio, and our established oncology development and commercial capabilities position us well to accelerate its progress. We look forward to working closely with the Georgiamune team to unlock the full potential of this innovative approach to benefit patients with cancer."

(Press release, Georgiamune, OCT 22, 2026, View Source [SID1234673682])

On October 22, 2026 HUYABIO International reported that oral HBI-8000 in combination with intravenous nivolumab reduced the risk of disease progression or death by 27% compared with nivolumab alone in a global Phase 3 trial involving patients with advanced melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), with median PFS of 11.7 months compared with 7.4 months for patients receiving nivolumab plus placebo. Together with its encouraging safety profile, the findings demonstrate the potential of HBI-8000 plus nivolumab to become an important new frontline treatment option for patients with advanced melanoma.

Data from the Phase 3 trial will be presented today in an oral Proffered Paper session at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 by Nikhil Khushalani, M.D., Vice-Chair for the Department of Cutaneous Oncology at the H Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.

Despite the dramatic impact of immunotherapy on patient outcomes in recent years, there is still an unmet need for new treatments that combine strong efficacy with greater convenience and acceptable tolerability. The combination of twice-weekly oral HBI-8000 with intravenous nivolumab offers a new approach that does not rely on dual immune checkpoint inhibitors, potentially reducing the risk of immune-related adverse reactions.

HBI-8000 is a highly differentiated selective Class I histone deacetylase (HDAC) inhibitor, designed to boost the immune response against cancer cells through epigenetic modification. By modifying the tumor microenvironment from non-responsive (‘cold’) to responsive (‘hot’), HBI-8000 has the potential to enhance the activity of anti-PD-1 checkpoint inhibitors such as nivolumab.

Dr. Khushalani, lead investigator for the study, said: "These results show, for the first time, that adding a selective HDAC inhibitor to anti-PD-1 therapy can improve treatment outcomes for patients with advanced melanoma. As a combination therapy that does not rely on dual immune checkpoint inhibition, the immunotoxicity profile is particularly significant given the risk of overlapping toxicities when two checkpoint inhibitors are used together. The fact that HBI-8000 is taken orally and has a predictable side-effect profile may offer advantages over dual checkpoint combinations currently in use."

Dr. Mireille Gillings, Founder and CEO of HUYABIO, said: "We are delighted to share these exciting results that demonstrate superior efficacy for advanced melanoma patients treated orally with HBI-8000. Immunotherapy has greatly improved clinical outcomes and now there is a new potential standard of care that extends progression free survival, minimizes immunotoxicity, and delivers better quality of life with greater convenience."

In the Phase 3 trial, which involved 404 patients across 15 countries, median PFS (mPFS) in the intention to treat (ITT) population was 11.7 months (95% CI: 7.3 – 21.1) with HBI-8000 plus nivolumab, compared with 7.4 months (95% CI: 4.5 to 10.1) for nivolumab plus placebo. The PFS hazard ratio (HR) was 0.73 (96% CI: 0.56 to 0.95; p=0.014), representing a 27% reduction in the risk of disease progression or death. PFS results favored HBI-8000 plus nivolumab across most prespecified subgroups. Overall survival (OS) data remain immature, with follow-up ongoing.

Adverse events associated with the HBI-8000 combination were consistent with the known safety profiles of the individual medicines. The incidence of Grade 3 and 4 treatment-related adverse events (TRAEs) was 54.8% in the HBI-8000 plus nivolumab arm and 17.9% in nivolumab plus placebo. The most common adverse events were diarrhea, nausea, cytopenia and fatigue. TRAEs were generally well-managed and the higher rate seen in the combination arm appeared consistent with the class effects of HDAC inhibition. Dose reductions of HBI-8000 were required in 38% of patients.

Importantly, there was no increase in cases of adrenal insufficiency or hypophysitis, two immune-related adverse events that are often irreversible and have a higher incidence with dual checkpoint inhibition.

HUYABIO International – a San Diego-headquartered company with unrivalled access to Chinese biopharmaceutical innovations, including HBI-8000 – plans to share the new data with the US Food and Drug Administration. The company also intends to engage with potential commercial partners as it works to bring the treatment to patients globally.

A manuscript detailing full results of the Phase 3 trial of nivolumab with or without HBI-8000 is being submitted for peer review.

Details of the ESMO (Free ESMO Whitepaper) Congress 2026 presentation

Abstract Number: LBA54 – Primary Analysis of HBI-8000-303: A Randomized Phase 3 Trial of Nivolumab plus HBI-8000 or Placebo in Advanced Melanoma

Presenter: Nikhil I. Khushalani, Moffitt Cancer Center, Tampa, FL, USA

Proffered Paper Session Details: Friday, October 23 at 16:15 – 17:45 CET in Barcelona Auditorium – Hall 9

(Press release, HUYA Bioscience, OCT 22, 2026, View Source [SID1234673681])

On October 22, 2026 ImmVira Group ("ImmVira") reported that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress. These presentations covered three key patient populations: 1) BCG-unresponsive high-risk carcinoma in situ (CIS); 2) BCG-unresponsive high-risk papillary (Ta/T1) tumors; and 3) BCG-naïve papillary (Ta/T1) tumors. The updated data showed encouraging clinical activity across the three patient populations, highlighting MVR-T3011’s broad therapeutic potential in bladder cancer and underscoring ImmVira’s comprehensive and long-term strategic commitment to this clinical landscape.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of the August 31, 2026 data cutoff, the updated poster presentations highlight the following key efficacy results:

Updated Phase II Study of MVR-T3011 in High-risk BCG-Unresponsive CIS NMIBC (E-poster FPN: 4792eP; NCT06971614)

The study enrolled 20 patients. Among them, 19 were evaluable for efficacy, receiving intravesical MVR-T3011 at either a 2×109 PFU (9 patients) or a 1×1010 PFU (10 patients) dose.
The 1×1010 PFU cohort achieved 88.9% and 87.5% complete response rate (CRR) at 6 months and 9 months respectively. The anytime CRR for the 1×1010 PFU dose reached 90% (9/10). This demonstrated superior response rates compared to the 2×109 PFU cohort, which achieved a 66.7% (6/9) anytime CRR.
Updated Phase II Study of MVR-T3011 in High-risk BCG-Unresponsive Papillary NMIBC (E-poster FPN: 4793eP; NCT06971614)

This cohort included 17 evaluable patients treated with the 2×109 PFU dose of MVR-T3011.
Patients achieved a 12-month recurrence-free survival (RFS) rate of 75.1%. Notably, 6 patients (6/17, 35%) successfully completed the full 2-year treatment course and remained recurrence-free.
Intravesical MVR-T3011 in BCG-Naïve High-Risk Papillary NMIBC (E-poster FPN: 4790eP)

Evaluating the therapy in a frontline setting, 15 patients were enrolled with 14 patients were evaluable. Patients were treated at the 1×1010 PFU dose.
Early results showcased robust clinical activity, with patients achieving a 92.9% RFS rate at 3 months. The RFS rate remained strong at 78.6% at 6 months, and 69.8% at both 9 and 12 months.
Across all three evaluated patient cohorts, MVR-T3011 demonstrated an excellent tolerability profile consistent with earlier clinical findings. The therapy maintained a highly manageable safety record even at the optimized higher doses, with no Grade 4 or higher treatment-related adverse events reported.

"Following our earlier presentation at ASCO (Free ASCO Whitepaper) 2026, we are highly encouraged to see the continuing clinical momentum and explosive potential of MVR-T3011 across broader NMIBC indications at this year’s ESMO (Free ESMO Whitepaper) Congress," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "These updated data further validate the therapy’s ability to provide a durable, highly effective, well-tolerated, and safe treatment option for bladder cancer patients. We remain fully committed to accelerating its clinical development to establish MVR-T3011 as an affordable, foundational novel treatment choice for bladder cancer patients worldwide, while actively expanding its clinical evaluation into late-stage muscle-invasive bladder cancer (MIBC) to offer a novel immunotherapy that enables bladder preservation and improves quality of life."

About MVR-T3011

MVR-T3011 represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations.

(Press release, Immvira, OCT 22, 2026, View Source [SID1234673680])

On October 22, 2026 ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, reported that its executive management team will participate in BIO-Europe 2026, held in Cologne, Germany, from November 9 to 11, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, ImmunoForge will engage in intensive 1-on-1 partnering sessions with global pharmaceutical leaders to present its core drug delivery platform technologies and advance Licensing-Out (L/O) and global co-development discussions for its lead clinical-stage oncology and rare disease pipelines.

Proprietary Platform Technologies

ELP (Elastin-Like Polypeptide) Platform: A versatile biopolymer technology enabling sustained drug delivery and circulating half-life extension by up to 200-fold. Utilizing a thermally responsive phase transition (VPGXG sequence), ELP forms a biocompatible depot upon subcutaneous administration, releasing therapeutic moieties smoothly without initial burst release, tissue toxicity, or viscosity-induced injection pain. The flexible platform supports both genetic fusion and site-specific chemical conjugation (Cys/Lys-free design) for peptides, proteins, and small molecules, transitioning dosing schedules from weekly to monthly while maintaining exceptionally low cost of goods (COGS) in standard expression systems (E. coli, yeast, mammalian).
LMT (Leptin Receptor-Mediated Transcytosis) Platform: An innovative Blood-Brain Barrier (BBB) shuttle platform designed for targeted central nervous system (CNS) delivery. By targeting the Leptin receptor (LepR)—which exhibits high brain specificity and low peripheral saturation compared to Transferrin or Insulin receptors—LMT minimizes peripheral loss and ligand competition. Preclinical data demonstrates that LMT (e.g., LMT15) enhances BBB penetration of diverse payloads, including proteins (>60 kDa), intact mitochondria, and Lipid Nanoparticles (LNPs) encapsulating mRNA/siRNA into crucial brain regions like the hypothalamus. Notably, ImmunoForge’s LMT platform was awarded 1st Place at the Novo Nordisk Partnering Day.
Lead Clinical & Oncology Pipelines

KF1601 (Next-Generation TKI for Drug-Resistant CML / ABL1 T315I Mutation): A novel, highly selective BCR-ABL1 tyrosine kinase inhibitor (TKI) designed to overcome drug resistance in Chronic Myeloid Leukemia (CML), specifically targeting the gatekeeper T315I mutation (~30% of drug-resistant cases) as well as wild-type and other major mutations. Preclinical studies demonstrate superior kinome selectivity and a significantly improved safety profile over current third-line TKIs (e.g., Ponatinib, Olverembatinib) by sparing KDR/VEGFR2, thereby eliminating arterial occlusive events and severe cardiovascular toxicity. Currently co-developed with a leading Korean pharmaceutical company for domestic Phase 1 trials, ImmunoForge retains exclusive Rest-of-World (RoW) rights (including US/EU) and is actively seeking global licensing partners.

PF1801 (Weekly GLP-1-ELP Fusion / Dermatomyositis & Polymyositis / DMD): A long-acting novel biological candidate leveraging the ELP platform. PF1801 acts directly on skeletal muscle membranes via GLP-1R signaling to suppress muscle cell necroptosis (PGAM5 inhibition via AMPK pathway) and stimulate muscle protein synthesis while inhibiting proteolytic degradation pathways. Granted US FDA Orphan Drug Designation (ODD), PF1801 is currently advancing through Phase 2 clinical trials in South Korea for Dermatomyositis/Polymyositis (DM/PM) and holds US FDA Phase 2 IND approval for Duchenne Muscular Dystrophy (DMD).

PF1804 (Weekly VPAC2 Agonist / DMD Cardiomyopathy): A long-acting VIP-ELP fusion protein engineered to target DMD-associated cardiomyopathy. By selectively activating the VPAC2 receptor, PF1804 exerts potent vasodilatory, anti-inflammatory, and anti-fibrotic effects, effectively preserving cardiac contractility and delaying heart function decline. PF1804 holds US FDA Orphan Drug Designation (ODD) and US FDA Phase 2 IND approval, presenting a validated, de-risked opportunity for global biopharma partners seeking high-value rare disease assets.
"BIO-Europe 2026 is an essential venue for ImmunoForge as we focus on executing strategic partnerships and licensing agreements for our lead clinical assets and platform technologies," said Sung-Min Ahn (MD, Ph.D.) and Ki-Ho Chang (MBA), Co-CEOs of ImmunoForge. "With a proven track record of multiple out-licensing deals—including agreements with global animal health companies and leading domestic pharmaceutical partners—we are eager to collaborate with global partners to maximize the therapeutic and commercial potential of KF1601, PF1801, PF1804, and our ELP/LMT platforms."

(Press release, ImmunoForge, OCT 22, 2026, View Source;phase-2-clinical-pipelines-at-bio-europe-2026-302917622.html [SID1234673679])